Logos Global Management LP acquired a new position in Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 539,079 shares of the company’s stock, valued at approximately $6,722,000. Logos Global Management LP owned 52.14% of Avalo Therapeutics at the end of the most recent reporting period.
Separately, Affinity Asset Advisors LLC grew its position in shares of Avalo Therapeutics by 350.0% in the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after buying an additional 35,000 shares during the period. Hedge funds and other institutional investors own 87.06% of the company’s stock.
Avalo Therapeutics Price Performance
Shares of NASDAQ AVTX opened at $9.67 on Tuesday. Avalo Therapeutics, Inc. has a 1 year low of $3.95 and a 1 year high of $52.75. The firm has a 50-day moving average of $9.88 and a 200 day moving average of $11.15.
About Avalo Therapeutics
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Read More
- Five stocks we like better than Avalo Therapeutics
- What is the Hang Seng index?
- Intel’s Spin-Off Strategy: A Bargain Hiding in Plain Sight?
- How to Evaluate a Stock Before Buying
- Workday’s Next-Gen AI Integration: Perfect Time to Buy the Dip?
- The 3 Best Fintech Stocks to Buy Now
- Seize the Growth: Twilio’s AI Innovations Are Driving Huge Upside
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.